New targeted radiation treatment reduces bone pain, extends survival in prostate cancer patients

August 23, 2013

Prostate cancer that has spread to the bones can cause pain and fractures.

Loyola University Medical Center is among the first hospitals in Chicago to offer a new targeted that can reduce bone pain and the incidence of fractures – and also extend patients' lives.

The treatment, recently approved by the Food and Drug Administration, is called Xofigo®. A , radium-223, is injected into the patient. Because it is similar to calcium, radium-223 binds to the bone. Radium-223 delivers high- over a short distance, providing a targeted treatment that is less damaging to other structures or tissues, said Robert Wagner, MD, medical director of Nuclear Medicine in Loyola's Department of Radiology.

Radium-223 is rapidly cleared from the blood stream. Fifteen minutes after injection, about 20 percent of the injected radioactivity remains in the blood. By 24 hours, less than 1 percent of radioactivity remains.

Xofigo is indicated for prostate cancer patients in which:

- the cancer has spread to the bones, but not to other organs

- the cancer is not responding to hormone therapy or surgery that blocks production of testosterone, and

- the cancer spread to the bones is causing other serious symptoms.

Radium-223 is injected into an IV line in a patient's vein, in a procedure that takes less than 5 minutes. The patient receives a series of six injections, given once every four to six weeks.

Side effects can include upset stomach, diarrhea, swelling in the hands and feet and decreased counts of , and platelets.

"While the treatment is not a cure, it can enable patients to live longer, with significantly improved quality of life," Wagner said.

Explore further: First Phase III trial of an alpha-pharmaceutical

Related Stories

First Phase III trial of an alpha-pharmaceutical

September 23, 2011

Until recently, options for patients with bone metastases from advanced prostate cancer have been very limited. But now the first Phase III study of an alpha-pharmaceutical in these patients has shown that it can prolong ...

New therapy extends life for prostate cancer patients

June 11, 2012

Prostate cancer patients with advanced tumors that have spread to bone have a poor chance of surviving. Patients with the disease may now live longer with a new line of radioisotope therapy, say researchers at the Society ...

Recommended for you

Compound doubles up on cancer detection

October 8, 2015

Tagging a pair of markers found almost exclusively on a common brain cancer yields a cancer signal that is both more obvious and more specific to cancer, according to a study published last week in the Proceedings of the ...


Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.